Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 401–500 of 972
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
“Isolation and quantification of peripheral blood mononuclear cells was carried out using methods and antibodies described in our laboratory [24].”
BackgroundMethodResultIncretin-based therapies for obesity treatment.
de Mello, A. H., Prá, M., Cardoso, L. C., Schraiber, R. D. B., & Rezin, G. (2015) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2015.05.012 · Cited by 29
Paschetta, E., Hvalryg, M., & Musso, G. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00897.x · Cited by 37
“Resistance to GIP incretin action may also reflect the down-regulation by ubiquitination of the GIP-R on pancreatic b-cells under chronic hyperglycaemia (79,106).”
BackgroundIrwin, N., McClean, P. L., Hunter, K., & Flatt, P. R. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01036.x · Cited by 36
Studies with GIP/Ins cells indicate secretion by gut K cells is KATPchannel independent
Wang, S. Y., Chi, M. M.-Y., Li, C., Moley, K. H., & Wice, B. M. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00398.2002 · Cited by 37
“In addition to effects on glucose homeostasis, GIP promotes obesity in mice fed a high-fat diet (33).”
BackgroundLymphatics in intestinal transport of nutrients and gastrointestinal hormones
Kohan, A. B., Yoder, S. M., & Tso, P. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05753.x · Cited by 36
Hasib, A., Ng, M. T., Gault, V. A., Khan, D., Parthsarathy, V., Flatt, P. R., & Irwin, N. (2016) · Diabetologia · doi:10.1007/s00125-016-4186-y · Cited by 33
“Similar to the conundrum regarding the clinical use of GIP receptor agonists or antagonists, both genetic knockout [49] and overexpression [50] of GIP has been shown to protect against obesity and development of diabetes.”
Baldassano, S., Gasbjerg, L. S., Kizilkaya, H. S., ROSENKILDE, M. M., Holst, J. J., & Hartmann, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00492 · Cited by 34
“In contrast, GIP stimulates LPL activity leading to triglyceride accumulation in cells (60, 61).”
BackgroundSelf-citationRecent advances of GIP and future horizons
Holst, J. J., & ROSENKILDE, M. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
Self-citationObesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 155
“Conversely, knockout of GIP receptor protects against diet induced obesity by increasing energy expenditure [84].”
BackgroundFurman, B. L., Pyne, N. J., Flatt, P. R., & O'Harte, F. P. M. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357044805 · Cited by 36
Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan
Tajiri, Y., Tsuruta, M., Ohki, T., Kato, T., Sasaki, Y., Tanaka, K., Kono, S., Tojikubo, M., & Yamada, K. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0248 · Cited by 34
Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
Sekar, R., Wang, L., & Chow, B. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00018 · Cited by 35
Lee, S., Yang, K. J. Z., Brun, P., Silvaroli, J. A., Yuen, J. J., Shmarakov, I. O., Jiang, H., FERANIL, J. B., Li, X., Lackey, A. I., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay8937 · Cited by 35
Antonini, S. R. R., N’Diaye, N., Baldacchino, V., Hamet, P., Tremblay, J., & Lacroix, A. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.03.120 · Cited by 37
Dekker, M. J., Graham, T. E., Ooi, T. C., & Robinson, L. E. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.08.004 · Cited by 32
“Furthermore, the pharmaceutical antagonism of GIPr prevented obesity and reduced TAG in mice fed various high-fat diets [49,50], and transgenic GIPr knockout mice have resisted the obesity and insulin resistance typically induced by a high-fat diet [51].”
BackgroundKirino, Y., Sato, Y., Kamimoto, T., Kawazoe, K., & Minakuchi, K. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00319.2010 · Cited by 37
“Recent studies have suggested that substrates for DPP4, such as GIP and neuropeptide Y1–36, play important roles in increased nutrient uptake, triglyceride accumulation, or antilipolytic activity in adipocytes (12, 15).”
BackgroundKawakami, Y., Watanabe, Y. S., Mazuka, M., Yagi, N., Sawazaki, A., Koganei, M., Natsume, M., Kuriki, K., Morimoto, T., Asai, T., et al. (2021) · Nutrition · doi:10.1016/j.nut.2020.111128 · Cited by 32
Using the lymphatics to study nutrient absorption and the secretion of gastrointestinal hormones
Kohan, A. B., Yoder, S. M., & Tso, P. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.056 · Cited by 35
“Diverse tissues, including liver, muscle, and adipose, express GIP receptors; interestingly, mice lacking the GIP receptor are resistant to diet-induced obesity [32].”
BackgroundMin, S. H., Yoon, J., Hahn, S., & Cho, Y. M. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12754 · Cited by 32
Watanabe, T., Tamura, Y., Kakehi, S., Funayama, T., Gastaldelli, A., Takeno, K., Kawaguchi, M., Yamamoto, R., Sato, F., Ikeda, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12262 · Cited by 31
Sloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Gasbjerg, L. S., Rasmussen, R. S., Dragan, A., Lindquist, P., Melchiorsen, J. U., Stępniewski, T. M., Schiellerup, S. P., Tordrup, E. K., Gadgaard, S., Kizilkaya, H. S., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16478 · Cited by 34
“For decades, there has been an interest in GIPR as a therapeutic target in the treatment of type 2 diabetes and obesity (Gasbjerg et al., 2018; Holst & Rosenkilde, 2020; Miyawaki et al., 2002; Nauck, Bartels, et al., 1993).”
Self-citationGIP-Dependent Expression of Hypothalamic Genes
AMBATI, S., DUAN, J., HARTZELL, D. L., CHOI, Y.-H., DELLA-FERA, M. A., & BAILE, C. A. (2011) · Physiological Research · doi:10.33549/physiolres.932151 · Cited by 31
“GIPR-/- mice were found to be resistant to diet-induced obesity and insulin resistance, and GIP has been considered as a potential pharmaceutical target in the treatment of diabetes, obesity and other metabolic disorders (Miyawaki et al. 2002, Kieffer 2003).”
BackgroundSankoda, A., Harada, N., Kato, T., Ikeguchi, E., Iwasaki, K., Yamane, S., Murata, Y., Hirasawa, A., & Inagaki, N. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13059 · Cited by 31
Regazzo, D., Barbot, M., Scaroni, C. M., Albiger, N. M. E., & Occhi, G. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09536-6 · Cited by 33
Vogel, C. I., Scherag, A., Brönner, G., Nguyen, T. T., Wang, H.-J., Grallert, H., Bornhorst, A., Rosskopf, D., Völzke, H., Reinehr, T., et al. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-19 · Cited by 30
“Under high fat diet Gipr-/- mice, in comparison to WT mice, have a reduced fat storage; they use fat as the main energy substrate and do not develop obesity, insulin resistance, diabetes mellitus, impaired glucose tolerance, and fatty liver like the WT [ 6 ,7,15-18].”
BackgroundInfluentialImmunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut
Morrow, N. M., Morissette, A., & Mulvihill, E. E. (2024) · Peptides · doi:10.1016/j.peptides.2024.171200 · Cited by 34
“…with T2DM [21,22] as well as evidence for an obesogenic role for GIP in genome-wide association studies [23,24] and preclinical studies in Gipr -/- mice demonstrating protection from diet-induced obesity and insulin resistance [25] originally barred GIP as a treatment for these metabolic diseases.”
Guccio, N., Gribble, F. M., & Reimann, F. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-113625 · Cited by 35
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 35
“Interestingly, Gipr−/− mice were found to be protected from high-fat diet (HFD)-induced obesity and insulin resistance, which was explained by a lower respiratory quotient and a preferred use of fat as an energy substrate [55].”
BackgroundShimotoyodome, A., Suzuki, J., Kameo, Y., & Hase, T. (2011) · British Journal of Nutrition · doi:10.1017/s0007114510005854 · Cited by 29
“The inhibition of either GIP signalling((23)) or GIP”
BackgroundSauber, J., Grothe, J., Behm, M., Scherag, A., Grallert, H., Illig, T., Hinney, A., Hebebrand, J., Wiegand, S., Grüters, A., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0444 · Cited by 31
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 37
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
“However, it has also been shown that GIP dose dependently increases LPL activity in differentiated 3T3-L1 adipocytes in the absence of insulin (Miyawaki et al. 2002).”
BackgroundInfluentialNogueiras, R. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0277 · Cited by 32
RNA-Seq Analysis of Enteroendocrine Cells Reveals a Role for FABP5 in the Control of GIP Secretion
Sommer, C., & Mostoslavsky, G. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1194 · Cited by 30
“ration (13) and induces an inflammatory response (16),”
BackgroundGlucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells
Prabakaran, D., Wang, B., Feuerstein, J. D., Sinclair, J. A., Bijpuria, P., Jepeal, L. I., & Wolfe, M. M. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.04.005 · Cited by 29
“[12] demonstrated that while normal mice became obese and developed insulin resistance and T2DM in response to a high-fat diet, GIPRdeficient (GIPR−/−) mice were protected and remained normal while consuming the identical diet.”
BackgroundMoffett, R. C., Irwin, N., Francis, J. M. E., & Flatt, P. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078560 · Cited by 31
“Thus, GIP has important regulatory effects on bone turnover, lipid metabolism and energy regulation [4–7].”
BackgroundSub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight
Szalowska, E., Meijer, K., Kloosterhuis, N., Razaee, F., Priebe, M. G., & Vonk, R. J. (2011) · Peptides · doi:10.1016/j.peptides.2011.02.011 · Cited by 31
Gastrointestinal peptides controlling body weight homeostasis
Zerón, H. M., López, M., & Diéguez, C. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.11.009 · Cited by 36
Gut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
From Bariatric to Pure Metabolic Surgery: New Concepts on the Rise
Santoro, S. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000590 · Cited by 30
Wean, J., Kowalsky, A. H., Laker, R., Will, S., Drucker, D. J., Rhodes, C. J., & Seeley, R. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102074 · Cited by 28
“The body weight effects in Figure 1 match published data for the GIPR KO and GIPR D GAT knockouts at room temperature [33,49] but two previous studies found that thermoneutrality negates the protective effect of both GLP-1R and GIPR knockouts on body weight [51,52].”
InfluentialAn integrative framework to prioritize genes in more than 500 loci associated with body mass index
Hemerich, D., Svenstrup, V., Díez‐Obrero, V., Preuss, M. H., Moscati, A., Hirschhorn, J. N., & Loos, R. J. F. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.04.016 · Cited by 29
The gut sensor as regulator of body weight
Reinehr, T., & Roth, C. L. (2014) · Endocrine · doi:10.1007/s12020-014-0518-1 · Cited by 30
“GIP receptor knockout mice are resistant to overfeeding [56].”
Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis
Pan, Y., Bu, T., Deng, X., Jia, J., & Yuan, G. (2024) · Endocrine · doi:10.1007/s12020-023-03640-z · Cited by 31
“Under the condition of a high-fat diet, mice lacking GIPRs preferred to take advantage of body fat as an energy substrate to reduce the deposition of triglyceride in the liver, which avoids obesity and IR [121].”
Tobin, L., Simonsen, L., & Bülow, J. (2011) · Clinical Physiology and Functional Imaging · doi:10.1111/j.1475-097x.2011.01041.x · Cited by 30
“Following a meal, the hormone GIP will stimulate and increase insulin secretion (Falko et al., 1975), and it has been suggested that GIP probably has indirect effects on the lipid metabolism (Beck & Max, 1983; Miyawaki et al., 2002).”
BackgroundShimazu‐Kuwahara, S., Harada, N., Yamane, S., Joo, E., Sankoda, A., Kieffer, T. J., & Inagaki, N. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.01.006 · Cited by 28
“Consistent with a role of GIP in fat accumulation, GIP receptor knockout mice were protected from weight gain and hepatic steatosis when placed on a high fat diet [12,49].”
BackgroundInfluentialFukuoka, D., Okahara, F., Hashizume, K., Yanagawa, K., Osaki, N., & Shimotoyodome, A. (2014) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00268.2014 · Cited by 30
Vahl, T. P., & D’Alessio, D. A. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000078991.96795.84 · Cited by 33
Mantelmacher, F. D., Fishman, S., Cohen, K., Pasmanik Chor, M., Yamada, Y., Zvibel, I., & Varol, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601441 · Cited by 27
“WT and Gipr mice maintain similar body weights when fed a regular diet (5, 8, 38).”
BackgroundSelf-citationIrwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Active immunization against (Pro 3 )GIP improves metabolic status in high‐fat‐fed mice
Montgomery, I. A., Irwin, N., & Flatt, P. R. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01228.x · Cited by 30
“Such a view is reinforced by studies conducted using GIP receptor knockout mice [11,14].”
BackgroundResultKirino, Y., Kamimoto, T., Sato, Y., Kawazoe, K., Minakuchi, K., & Nakahori, Y. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.463 · Cited by 30
Ben‐Shlomo, S., Zvibel, I., Varol, C., Spektor, L., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2013) · Obesity · doi:10.1002/oby.20340 · Cited by 28
“Furthermore, inhibition of GIP binding to its receptor using 1 lM of the GIP antagonist GIP (7-30) prevents the GIP-mediated increase in adiponectin levels (Figure 5A and 5B).”
BackgroundMethodResultInfluentialItoh, K., Moriguchi, R., Yamada, Y., Fujita, M., Yamato, T., Oumi, M., Holst, J. J., & Seino, Y. (2014) · Nutrition Research · doi:10.1016/j.nutres.2014.07.013 · Cited by 27
“However, GIP secretion is stimulated immediately by high fat intake, and GIP stimulation may be the principle factor, because insulin resistance is ameliorated by the inhibition of GIP signaling [23].”
BackgroundSelf-citationThe Anti-fatigue Effects of the Low-Molecular-Weight Fraction of Bonito Extract in Mice
Nozawa, Y., Yamada, K., Okabe, Y., Ishizaki, T., & Kuroda, M. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.468 · Cited by 28
Miyachi, A., Murase, T., Yamada, Y., Osonoi, T., & Harada, K. (2013) · Journal of Proteome Research · doi:10.1021/pr400069f · Cited by 30
Self-citationAre peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Gribble, F. M., Reimann, F., & Roberts, G. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00002-5 · Cited by 30
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
“Accordingly, it has been shown that obesity-associated metabolic disturbances could be reduced by the chemical and genetic ablation of GIP receptor signaling in mice (102, 128).”
BackgroundDuez, H., Smith, A. C., Xiao, C., Giacca, A., Szeto, L., Drucker, D. J., & Lewis, G. F. (2008) · Endocrinology · doi:10.1210/en.2008-1137 · Cited by 30
“Intriguingly, although GIP receptor (GIPR) agonists potentiate GSIS, GIP antagonists, or genetic ablation of the GIPR gene produces a complex metabolic phenotype reflecting the integrated importance of GIP for the function of both -cells and adipose tissue (8, 9).”
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
“Mice without GIP receptors are lean without weight gain when fed a high-fat diet [53].”
BackgroundMikada, A., Narita, T., Yokoyama, H., Yamashita, R., Horikawa, Y., Tsukiyama, K., & Yamada, Y. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.040 · Cited by 27
“accumulating effects in animal over-nutrition states [10,11] and the results of our recent report of significant BW reduction with simultaneous decreased GIP and IRI levels with a-GIs [5].”
BackgroundSelf-citationYanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Atageldiyeva, K. K., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., & Haneda, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3842-y · Cited by 26
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Maekawa, R., Ogata, H., Murase, M., Harada, N., Suzuki, K., Joo, E., Sankoda, A., Iida, A., Izumoto, T., Tsunekawa, S., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00352.2017 · Cited by 28
“To address the role of GIP in the control of glucose metabolism and body weight gain, several animal models have been-analyzed (2, 6, 16, 19, 25, 26, 28, 39).”
BackgroundMethodInfluentialSelf-citationYang, J., Gao, Z., Williams, D. B., Wang, C., Lee, S., Zhou, X., & Qiu, P. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.06.003 · Cited by 27
The early history of GIP 1969–2000: From enterogastrone to major metabolic hormone
Marks, V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170276 · Cited by 27
Anti‐inflammatory role of glucose‐dependent insulinotropic polypeptide in periodontitis
Suzuki, Y., Nakamura, N., Miyabe, M., Nishikawa, T., Miyajima, S., Adachi, K., Mizutani, M., Kikuchi, T., Miyazawa, K., Goto, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12450 · Cited by 26
Self-citationModeling drug action in the mouse with knockouts and RNA interference
Zambrowicz, B., & Sands, A. (2004) · Drug Discovery Today TARGETS · doi:10.1016/s1741-8372(04)02454-5 · Cited by 31
Adaptive selection of an incretin gene in Eurasian populationsPreprint
Chang, C. L., Cai, J. J., Lo, C., Amigo, J., Park, J.-I., & Hsu, S. Y. (2010) · Genome Research · doi:10.1101/gr.110593.110 · Cited by 26
“Abnormal regulation of GIP signaling leads to altered carbohydrate metabolism and lipid accumulation at the enteroinsular and enteroadipocyte axis, respectively (Miyawaki et al. 2002; Fulurija et al. 2008; Isken et al. 2008; Kim and Egan 2008).”
BackgroundInvestigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 26
“In line with this, the genetic deletion of GIP(??) and GIPR or the direct ablation of GIP-secreting K cells prevented diet-induced obesity in mouse models [138–140].”
BackgroundTimper, K., Grisouard, J., Radimerski, T., Dembinski, K., Peterli, R., Häring, A., Frey, D. M., Zulewski, H., Keller, U. B., Müller-Stich, B. P., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1324 · Cited by 27
Novel extrapancreatic effects of incretin
Yamada, Y., Tsukiyama, K., Sato, T. K., Shimizu, T., Fujita, H., & Narita, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12495 · Cited by 27
“GLP-1 (7-37) and GLP-1(7-36) amide were shown to be released from intestinal L cells, and stimulate insulin secretion from pancreatic b-cells directly(6).”
BackgroundSelf-citationKoenitzer, J. D., Pramanick, S., Pan, Q., Augustin, R., Bandholtz, S., Harriman, W. D., & Izquierdo, S. M. (2017) · mAbs · doi:10.1080/19420862.2016.1276683 · Cited by 26
Sánchez, J., Picó, C., Ahrens, W., Foraita, R., Fraterman, A., Moreno, L. A., Russo, P., Siani, A., Palou, A., & Consortia, O. B. O. T. I. A. I. F. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.132 · Cited by 25
Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus
Vilsbøll, T., & Knop, F. K. (2008) · BioDrugs · doi:10.2165/00063030-200822040-00004 · Cited by 25
“[1,2] ism.[9] The action of both hormones, which is exerted by interaction with specific G-protein-coupled receptors on the pancreatic β cells, consists of potentiation of glucose-induced insulin secretion, and 1.”
Sachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01940-2 · Cited by 24
Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
Al-Zamel, N., Al‐Sabah, S., Luqmani, Y. A., Adi, L., Chacko, S., Schneider, T. D., & Krasel, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143532 · Cited by 25
“Interest in GIPR antagonists developed after studies where GIPR knockout mice were shown to be resistant to diet-induced obesity [25].”
BackgroundSeeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“In addition, double-homozygous Gipr − / − ob / ob mice gained less weight and had lower adiposity than wild-type ob / ob mice ( 149 ).”
BackgroundThe antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 28
Nakamura, T., Tanimoto, H., Mizuno, Y., Tsubamoto, Y., & Noda, H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01555.x · Cited by 26
“GIP receptor knock-out mice fed on high-fat diets actually showed a suppression of body weight compared with wild-type mice who were fed the same high-fat diets [24], and long-term administration of the GIP receptor antagonist, (Pro3)GIP, also prevented obesity and insulin resistance in mice [25,26].”
BackgroundSelf-citationKerr, B. D., Flatt, A. J., Flatt, P. R., & Gault, V. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.077 · Cited by 24
The emerging role of the intestine in metabolic diseases
Bradley, W. D., Zwingelstein, C., & Rondinone, C. M. (2011) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2011.578651 · Cited by 30
“elimination of GIP signalling promotes resistance to obesity in rodents (Irwin & Flatt, 2009; Miyawaki et al., 2002; Nauck et al., 1993a).”
BackgroundOverview of bariatric surgery for the physician
Hng, K. N., & Ang, Y. S. (2012) · Clinical Medicine · doi:10.7861/clinmedicine.12-5-435 · Cited by 25
Gastrointestinal Hormones and Neurotransmitters
Liddle, R. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00001-9 · Cited by 25
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
“…activity of GIP in adipocytes has been investigated for some time, and although there is a need for better understanding, GIP is implicated in adipocyte carbohydrate and lipid metabolism through regulation of glucose uptake [30], lipolysis [31], and lipoprotein lipase (LPL) activity [32].”
Rubinić, I., Kurtov, M., & Likić, R. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1243 · Cited by 27
“39,40 40-42 Tirzepatide, a GIPR/ GLP-1R agonist, has demonstrated efficacy in reducing body weight in both murine models and humans.”
BackgroundSelectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells
Al‐Sabah, S., Al-Fulaij, M. A., & Ahmed, H. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.019 · Cited by 23
NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1–30)amide
Alaña, I., Hewage, C. M., Malthouse, J. P. G., Parker, J. C., Gault, V. A., & O'Harte, F. P. M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.033 · Cited by 23
Chondronikola, M., Porter, C. C., Malagaris, I., Nella, A. A., & Sidossis, L. S. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0958 · Cited by 29
Murata, Y., Harada, N., Yamane, S., Iwasaki, K., Ikeguchi, E., Kanemaru, Y., Harada, T., Sankoda, A., Shimazu‐Kuwahara, S., Joo, E., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00200.2018 · Cited by 28
“In addition, long-term HFD intake causes GIP hypersecretion (30), most likely due to increased GIP gene expression (5) via transcriptional factor regulatory factor X6 (Rfx6) and pancreatic and duodenal homeobox 1 (Pdx1) (13, 50).”
BackgroundGPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve
Ueno, H., Ito, R., Abe, S., Ogino, H., Maruyama, M., Miyashita, H., Miyamoto, Y., Moritoh, Y., Tsujihata, Y., Takeuchi, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222653 · Cited by 23
“GIP is known to be secreted in response to fat-rich meals [42], and plasma levels of GIP were reported to be affected by meals to a larger extent than those of GLP-1 [43].”
BackgroundSun, L., Goh, H. J., Govindharajulu, P., Leow, M. K., & Henry, C. J. (2019) · Foods · doi:10.3390/foods8120634 · Cited by 23
“It promotes the efficient storage of ingested fats, and may play a pivotal role in the development of obesity due to chronic over nutrition [10].”
BackgroundAbsence of GIP secretion alleviates age-related obesity and insulin resistance
Kanemaru, Y., Harada, N., Shimazu‐Kuwahara, S., Yamane, S., Ikeguchi, E., Murata, Y., Kiyobayashi, S., Hatoko, T., & Inagaki, N. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0477 · Cited by 26
Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22
Roberts‐Thomson, K. M., Parker, L., Betik, A. C., Wadley, G. D., Gatta, P. A. D., Marwick, T. H., & Keske, M. A. (2022) · The Journal of Physiology · doi:10.1113/jp282428 · Cited by 22
“Interestingly, mice lacking the GIP receptor are protected against high fat diet-induced obesity and insulin resistance (Miyawaki et al. 2002).”
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.